» Articles » PMID: 36389264

CMR Findings in Patients Referred for Suspected Myocarditis Following MRNA-based COVID Vaccination Compared with Pre-COVID Myocarditis Referrals: A Single-centre Observational Study

Overview
Date 2022 Nov 17
PMID 36389264
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Vaccination is considered the key to overcome the COVID pandemic. For the first time mRNA-based vaccinations are used in humans. Case series suggested an increased risk of myocarditis after vaccination. This study sought to describe CMR findings in patients with suspected mRNA-vaccine associated myocarditis.

Methods: A total of 33 consecutive patients referred for CMR work-up of suspected myocarditis associated with mRNA-based vaccination were included. A historical cohort of 135 consecutive patients referred for suspected myocarditis in the pre-COVID era served as control group. All patients underwent multi-parametric CMR including CINE and late gadolinium enhancement (LGE) imaging as well as parametric T1/T2 mapping of the left ventricular myocardium.

Results: Patients referred for suspected vaccination-related myocarditis were more often female (55 % vs 32 %, p = 0.015) and demonstrated smaller LV dimensions as well as a better LV function compared to patients of the control group. CMR revealed a lower prevalence of non-ischemic LGE in patients with suspected vaccination-myocarditis (6 % vs 22 %, p = 0.04). However, among patients without LGE we observed a higher prevalence of an abnormal T1/T2 mapping result in patients with suspected vaccination-myocarditis compared to the control group (45 % vs 18 %, p = 0.010).

Conclusion: In this small single-centre study, compared to myocarditis referrals in the pre-COVID era, patients currently referred for CMR work-up of suspected mRNA-vaccination-associated myocarditis demonstrated lower prevalence of LGE but higher prevalence of abnormal T1/T2 mapping. These hypothesis-generating observations may point towards a rather subtle myocardial damage and support the routine use of T1/T2 mapping in this indication.

Citing Articles

Recent highlights on myocarditis and cardiomyopathies from the and .

Conti N, Ammirati E, Tedeschi A, Dobrev D Int J Cardiol Heart Vasc. 2023; 49:101315.

PMID: 38076350 PMC: 10698246. DOI: 10.1016/j.ijcha.2023.101315.

References
1.
Oster M, Shay D, Su J, Gee J, Creech C, Broder K . Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022; 327(4):331-340. PMC: 8790664. DOI: 10.1001/jama.2021.24110. View

2.
Grani C, Eichhorn C, Biere L, Murthy V, Agarwal V, Kaneko K . Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol. 2017; 70(16):1964-1976. PMC: 6506846. DOI: 10.1016/j.jacc.2017.08.050. View

3.
Eichhorn C, Greulich S, Bucciarelli-Ducci C, Sznitman R, Kwong R, Grani C . Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis. JACC Cardiovasc Imaging. 2022; 15(7):1325-1338. DOI: 10.1016/j.jcmg.2021.11.017. View

4.
Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H . Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004; 109(10):1250-8. DOI: 10.1161/01.CIR.0000118493.13323.81. View

5.
Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View